Patients with hematologic malignancies often have a complex array of medical issues. Our Program for Hematologic Malignancies brings together a team of specialists to provide patients with individualized treatment plans without duplicating services. Patients are evaluated by:
Specialized nurses, nurse practitioners, and research nurses
The Program for Hematologic Malignancies offers a comprehensive range of diagnostic
and treatment services designed to provide patients with the most effective
care possible. Services include:
On-site specialized diagnostic and support services, including hematopathology,
molecular diagnosis, immunophenotyping, special cell component therapy and
pheresis, and infectious disease specialists
Integrated programs with the Blood and Marrow Transplant Program
We also treat benign hematology bleeding disorders, red cell disorders,
platelet abnormalities and white cell disorders.
A major goal of Hematologic Malignancies Program is to develop new curative
approaches for leukemias, lymphomas and myelomas. For example:
We offer a number of NCI-funded Phase I and II innovative clinical trials
of new drugs and novel drug combinations for patients with newly diagnosed
or relapsed and/or refractory leukemias and myelodysplasia.
We use novel immunotherapy approaches to treat Chronic Myelogenous Leukemia
(CML), lymphoma and multiple myeloma.
We offer new molecularly-targeted drugs for multiple myeloma.
If you would like to make an appointment, or if you are a physician with a patient who would benefit from the expertise and treatment we offer, please call us at 1-800-888-8823